Sep 14, 2018, 01:00 by admin admin

Sep 14, 2018, 01:00 by admin admin

ASAM submitted a letter to the Senate Health, Labor, and Pensions (HELP) Committee asking that benefit protections for mental health and substance use disorder treatment and recovery support services through the exchanges and individual/small group markets be maintained and that those benefits be offered consistent with the Mental Health Parity and Addiction Equity Act (MHPAEA as the committee works to develop a market stabilization framework.

Sep 14, 2018, 01:00 by admin admin

This Policy Statement includes recommendations on standards related to the marketing of addiction treatment services and recruiting of patients as well as state and federal government development and dissemination of materials for consumers to detect potential fraudulent marketing and patient recruiting practices.

Sep 14, 2018, 01:00 by admin admin

On behalf of the Mental Health Liaison Group (MHLG), we are writing to express our opposition of specific provisions within the House and Senate versions of the Tax Cuts and Jobs Act, particularly the provisions repealing the Affordable Care Act’s individual shared responsibility mandate and the House’s provision repealing the medical expense deduction. 

Sep 14, 2018, 01:00 by admin admin

ASAM signed onto a letter led by the Ohio Society of Addiction Medicine (OHSAM), along with several other Ohio health care groups. The letter urged the Ohio Department of Medicaid (ODM) to require Medicaid managed care plans to use nationally recognized clinical standards, such as ASAM’s, when determining coverage standards for substance use disorder services.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted two comment letters to the Food and Drug Administration (FDA) regarding new subcutaneous injectable buprenorphine formulations. In the letters, ASAM reiterated support for new pharmacotherapies for addiction and that patients should have a robust and varied array of treatment options. The letters also highlighted that these new formulations of would be injected one or twice monthly and have the potential to decrease diversion.

Sep 14, 2018, 01:00 by admin admin

ASAM led a letter signed by 432 health organizations sharing concerns with the most recent version of the American Health Care Act (AHCA).

Sep 14, 2018, 01:00 by admin admin

ASAM and the Partnership to Amend 42 CFR Part 2 (Partnership) sent a letter strongly supporting the Overdose Prevention and Patient Safety (OPPS) Act, H.R. 3545, which would align 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of health care treatment, payment, and operations (TPO).

Sep 14, 2018, 01:00 by admin admin

Yesterday, President Trump’s Commission on Combating Drug Addiction and the Opioid Epidemic held its fifth and final meeting during which the commission approved its final report to the president.

Sep 14, 2018, 01:00 by admin admin

ASAM and the Ohio Society of Addiction Medicine (OHSAM) sent a letter to the State of Ohio Board of Pharmacy and the Department of Mental Health and Addiction Services asking them to provide education and clarity to providers of office-based opioid treatment (OBOT) on new proposed rules.

Sep 14, 2018, 01:00 by admin admin

Today, the American Society of Addiction Medicine (ASAM) applauded U.S. Surgeon General Jerome M. Adams, MD, MPH, for encouraging more individuals, including family, friends, and those at risk for opioid overdose, to keep on hand naloxone, an FDA-approved medication that can reverse opioid-induced respiratory depression.

Sep 14, 2018, 01:00 by admin admin

ASAM and the Wisconsin Society of Addiction Medicine submitted a letter to the Wisconsin Department of Health Services (DHS), Division of Medicaid Services on its proposed amendments to provisions of its Section 1115 Demonstration Waiver (BadgerCare Reform Demonstration Waiver).

Sep 14, 2018, 01:00 by admin admin

ASAM joined 145 members of the Coalition to Stop Opioid Overdose and other organizations in sending a letter voicing support for the CARE Act of 2019. This legislation 2019 would provide $100 billion in federal funding over the next ten years to support federal research and programs to prevent drug use while expanding access to prevention, harm reduction, addiction treatment, mental health services, and recovery support services.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted recommendations on the White House Opioid Commission’s Interim Report. The Interim Report outlines recommendations from the commission to inform the White House of the best methods to combat the opioid epidemic.

Sep 14, 2018, 01:00 by admin admin

ASAM and the New York Society of Addiction Medicine (NYSAM) submitted comments on emergency proposed regulations to align state law with federal law to allow NPs and PAs to prescribe buprenorphine for addiction treatment.

Sep 14, 2018, 01:00 by admin admin

ASAM and the New Jersey Society of Addiction Medicine (NJSAM) submitted letters of support with recommended revision for A4138 and S1051, legislation that would require state insurance providers to cover the costs of buprenorphine and prohibit utilization controls.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted comments on proposed revised regulations in Delaware to restrict opioid prescribing via telemedicine to only permit the prescribing of medications used to treat addiction, such as buprenorphine.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted comments regarding SAMHSA's Supplemental Notice of Proposed Rulemaking (SNPRM) on the Confidentiality of Substance Use Disorder Patient Records (42 CFR part 2).

Sep 14, 2018, 01:00 by admin admin

ASAM led a coalition letter signed by 465 organizations sharing serious concerns regarding the Better Care Reconciliation Act (BCRA). The letter emphasized how the BCRA’s proposed changes to the health care system will result in reductions in health care coverage, particularly for vulnerable populations including those suffering from substance use disorders and mental illness.

Sep 14, 2018, 01:00 by admin admin

The American Society of Addiction Medicine (ASAM) and the American Medical Association (AMA) jointly announced today the release of a concept paper detailing a groundbreaking alternative payment model (APM) that could revolutionize how patients with opioid use disorder are treated.